Tumor estimation accuracy enhanced with new TissueMark release

Royal Philips uses artificial intelligence and advanced analytics in key healthcare areas. Ovarian cancer has the fifth highest mortality rate for women, and prostate cancer has the second highest mortality rate for men, so Philips’ newest version of its TissueMark, with region of interest detection for most molecular testing, tumor sufficiency guidance to whole slide images of adenocarcinoma prostate tissue and high-grade serous carcinoma ovarian tissue, and improved accuracy of tumor estimation are all welcome upgrades. It also provides tumor sufficiency guidance for lung cytology, lung histology, breast tissue and colon samples in 60 seconds.
Marlon Thompson, general manager at Philips Digital & Computational Pathology, said: “Using a microscope for tumor estimation is subjective and leads to high variability amongst pathologists. By digitizing the tissue slide and analyzing the image with robust computational software and intelligent algorithms, we can better support pathologists’ workflows and help labs enhance quality and reliability, while reducing costs by limiting the number of molecular tests performed with insufficient tumor content.”